• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Comparison of MRI, [18F]FDG-PET/CT, and [18F]FDG-PET/MRI for Initial Staging of Multiple Myeloma: A Systematic Review and Meta-analysis

by MM360 Staff | Jul 13, 2025 | Publications

Clin Nucl Med. 2025 Jul 8. doi: 10.1097/RLU.0000000000006048. Online ahead of print. ABSTRACT PURPOSE: This systematic review and meta-analysis compared the diagnostic performance of MRI, [18F]FDG-PET/CT, and [18F]FDG-PET/MRI in detecting focal bone lesions and bone...

Incidence and prevalence of light chain amyloidosis in the United States in 2019–2021 using Optum EHR data

by MM360 Staff | Jul 12, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Interleukin-6 is a highly prognostic biomarker for POEMS syndrome

by MM360 Staff | Jul 12, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Targeting proteostasis in multiple myeloma through inhibition of LTK

by MM360 Staff | Jul 9, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

IsaKRD Induction Achieves 95% Response Rate in Multiple Myeloma

by MM360 Staff | Jul 9, 2025 | Myeloma News

Source: Pharmacy Times articles New data reveals isatuximab-based therapy achieves high MRD-negativity rates in newly diagnosed multiple myeloma. Read More
« Older Entries
Next Entries »

Recent Content

  • Mobilization of hematopoietic stem cells using G-CSF with or without cyclophosphamide before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma receiving induction therapy with or without daratumumab
  • Incidence and prevalence of clinically detected smoldering multiple myeloma within the general population: a retrospective observational cohort study
  • The long non-coding RNA CRNDE stabilises SIRT1 protein and influences Hedgehog signalling in multiple myeloma
  • What Does Multiple Myeloma Mean?
  • FDA Update: Darzalex Faspro Not Approved for Multiple Myeloma
  • Temporal genomic dynamics shape clinical trajectory in multiple myeloma
  • Bone Marrow Microenvironments Vary Widely in Multiple Myeloma, Study Finds
  • Safety and efficacy of BCMA CAR-T vs. bispecific antibodies in patients with relapsed multiple myeloma: a systematic review and meta-analysis
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
  • Why New Patients With Multiple Myeloma ‘Can Expect Long, Healthy Lives’
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT